Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "API"

2392 News Found

Aragen secures $100 million investment from Quadria Capital
News | January 13, 2025

Aragen secures $100 million investment from Quadria Capital

Investment will fund expansion to meet rising demand for CRDMO services


Aarti Drugs receives EIR from USFDA for Tarapur API facility
Drug Approval | December 26, 2024

Aarti Drugs receives EIR from USFDA for Tarapur API facility

This facility is considered to be in a minimally acceptable state of compliance with regard to current GMP


Briefs: Gandhar Oil Refinery India, FDC and Apitoria Pharma
Drug Approval | December 22, 2024

Briefs: Gandhar Oil Refinery India, FDC and Apitoria Pharma

FDC Ltd has received final approval from USFDA for the company's Abbreviated New Drug Application (ANDA) for Cefixime 400 mg Tablets


Supriya Lifescience inaugurates Rs. 125 crore new API production block in Maharashtra
News | December 17, 2024

Supriya Lifescience inaugurates Rs. 125 crore new API production block in Maharashtra

The facility houses 33 reactors, comprising stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL


Merck recommends rejection of TRC Capital’s “Mini-Tender” Offer
News | November 23, 2024

Merck recommends rejection of TRC Capital’s “Mini-Tender” Offer

The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024


Shilpa Pharma Lifesciences received CEP from EDQM for API, Octreotide
Drug Approval | November 19, 2024

Shilpa Pharma Lifesciences received CEP from EDQM for API, Octreotide

Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis


Shilpa Pharma Lifesciences receives CEP from EDQM for API, Desmopressin
Drug Approval | October 04, 2024

Shilpa Pharma Lifesciences receives CEP from EDQM for API, Desmopressin

This is used to treat central diabetes insipidus and bedwetting


Apitoria Pharma gets Form 483 with 10 observations from USFDA
Drug Approval | October 01, 2024

Apitoria Pharma gets Form 483 with 10 observations from USFDA

The observations are of procedural in nature and will be responded to within the stipulated time


DevCo completes strategic capital raise for investment in Medix Biochemica
News | September 23, 2024

DevCo completes strategic capital raise for investment in Medix Biochemica

The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives